Comparison
Citicoline vs MOTS-c
Side-by-side of Citicoline and MOTS-c. Every row below is pulled from the compound schema and will update as our data grows. For deeper reads, follow through to each compound page.
Citicoline
Citicoline supplement profile: CDP-choline as a phosphatidylcholine precursor, Cognizin dosing 250-2000 mg, cognition trials, stroke recovery evidence.
MOTS-c
MOTS-c peptide is a 16-amino-acid mitochondrial-derived peptide. Preclinical signals for insulin sensitivity, exercise capacity, dosage notes.
Effects at a glance
Citicoline
- •Choline donor and phosphatidylcholine precursor; oral bioavailability roughly 99%
- •Standard prescription medication for stroke recovery and vascular cognitive impairment in much of the world
- •Healthy-adult cognitive trials (Cognizin) report small gains in attention and working memory at 250 to 500 mg/day
- •ICTUS trial (n=2,298) was negative on stroke recovery in the modern thrombolysis era
- •Lower per-gram choline content than alpha-GPC (~18% vs ~40%), meaning smaller TMAO load at equivalent dose
- •Long uridine half-life (~56 hours) supports once or twice daily dosing
MOTS-c
- •16-amino-acid peptide encoded in mitochondrial DNA (12S rRNA region); discovered 2015
- •Activates AMPK in skeletal muscle and liver; improves insulin sensitivity in rodent models
- •Circulating endogenous levels decline with age, motivating the longevity-restoration hypothesis
- •CohBar's MOTS-c analog CB4211 discontinued after phase 1b NASH readout did not meet endpoints
- •Anecdotal protocols use 5 to 10 mg subcutaneously 2 to 3 times weekly
- •Not on the WADA Prohibited List as of 2026; future scrutiny likely given exercise-mimetic mechanism
Side-by-side
| Attribute | Citicoline | MOTS-c |
|---|---|---|
| Category | supplement | peptide |
| Also known as | CDP-choline, cytidine 5'-diphosphocholine, Cognizin | Mitochondrial Open Reading Frame of the Twelve S rRNA-c, MOTSc |
| Half-life (hr) ↗ | 56 | 0.5 |
| Typical dose (mg) ↗ | 500 | 5 |
| Dosing frequency | 1 to 2 times daily | 2-3x weekly |
| Routes | oral, intravenous | subcutaneous |
| Onset (hr) | 1 | 1 |
| Peak (hr) | 2 | 4 |
| Molecular weight | 488.32 | 1880.18 |
| Molecular formula | C14H26N4O11P2 | C82H132N22O25S2 |
| Mechanism | Hydrolyzed to cytidine and choline after absorption; both cross the blood-brain barrier and are recombined intracellularly to reform CDP-choline, supporting phosphatidylcholine synthesis and acetylcholine production. | Mitochondrial-derived peptide that activates AMPK in skeletal muscle and liver, improves insulin sensitivity, and translocates to the nucleus under metabolic stress to modulate nuclear gene expression in retrograde mitochondrial signaling. |
| Legal status | Dietary supplement (US, Cognizin GRAS); prescription medication in most of the world | Not FDA approved; research-use-only grey market; not currently on WADA Prohibited List |
| WADA status | allowed | unknown |
| DEA / Rx | OTC supplement (US); Rx in most of the world | Not scheduled (research chemical) |
| Pregnancy | Insufficient data for routine use | Insufficient data; not recommended |
| CAS | 987-78-0 | 1627580-64-6 |
| PubChem CID | 13804 | 139599184 |
| Wikidata | Q411470 | Q24832108 |
Safety profile
Citicoline
Common side effects
- mild GI upset
- headache
- restlessness
- occasional insomnia with evening dosing
Contraindications
- concurrent strong anticholinergic therapy
- established cardiovascular disease (TMAO concern, smaller than alpha-GPC)
Interactions
- anticholinergic medications: partial mutual antagonism(minor)
- cholinesterase inhibitors: additive cholinergic effect(minor)
- antimetabolite chemotherapy (5-FU): theoretical cytidine pathway interaction(minor)
MOTS-c
Common side effects
- injection-site irritation
- transient fatigue
- headache (anecdotal)
Contraindications
- pregnancy
- lactation
- active malignancy (theoretical)
- severe hypoglycemia risk on concurrent insulin or sulfonylurea
Interactions
- insulin: additive insulin sensitization may increase hypoglycemia risk(moderate)
- metformin: both activate AMPK; theoretical additive metabolic effect, no controlled data(minor)
- sulfonylureas: increased hypoglycemia risk via additive insulin sensitization(moderate)
Which Should You Take?
Citicoline comes out ahead for most readers on the criteria we weight: 3 catalogued goals, OTC dietary supplement, oral dosing, with a Tier-B outcome catalogued. MOTS-c is the right call when one of the conditionals below applies.
- → If your priority is focus or working memory, pick Citicoline.
- → If your priority is stroke recovery, pick Citicoline.
- → If your priority is healthspan extension, pick MOTS-c.
- → If your priority is metabolic health and glucose control, pick MOTS-c.
Edge case: If you want to avoid research-only / gray-market sourcing, Citicoline is the more accessible choice.
Default choice: Citicoline. Lower friction to source, and broader goal coverage. Reach for MOTS-c only if your priority sits squarely in the goals it owns above.
This verdict is generated from each compound's schema (goals, legal status, evidence outcomes, dosing route). It updates automatically as our compound data evolves; the deeper read sits on each individual compound page.
Common questions
What is the difference between Citicoline and MOTS-c?
Citicoline and MOTS-c differ in category (supplement vs peptide), mechanism, and typical dosing. See the side-by-side table for full details.
Which has a longer half-life, Citicoline or MOTS-c?
Citicoline half-life is 56 hours; MOTS-c half-life is 0.5 hours.
Can you stack Citicoline with MOTS-c?
Stack compatibility depends on mechanism overlap, legal status, and individual response. Check each compound page for specific interactions and contraindications before combining.
Go deeper